Nautilus Biotechnolgy
NAUT
86 hedge funds and large institutions have $120M invested in Nautilus Biotechnolgy in 2022 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 20 increasing their positions, 23 reducing their positions, and 8 closing their positions.
38% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 8
4% more funds holding
Funds holding: 83 → 86 (+3)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0.92% less ownership
Funds ownership: 46.2% → 45.28% (-0.92%)
13% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 23
23% less capital invested
Capital invested by funds: $155M → $120M (-$35M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$448K |
| 2 |
BM
Bridger Management
New York
|
+$314K |
| 3 |
State Street
Boston,
Massachusetts
|
+$181K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$108K |
| 5 |
SGM
Skye Global Management
West Palm Beach,
Florida
|
+$81.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
-$1.26M |
| 2 |
CAM
Crown Advisors Management
Larkspur,
California
|
-$672K |
| 3 |
ABG
Ally Bridge Group
New York
|
-$645K |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$326K |
| 5 |
Millennium Management
New York
|
-$303K |
NAUT Hedge Fund Activity: Q3 2022 in Review
86 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Nautilus Biotechnolgy (NAUT) for Q3 2022, worth a combined $120M — down 23% from $155M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new NAUT positions and 8 closed out — a net gain of 3 holders — while 20 added to existing stakes and 23 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $448K. The largest seller was RTW Investments, cutting an estimated $1.26M.
- 86 institutional investors held Nautilus Biotechnolgy (NAUT) as of Q3 2022, up from 83 in Q2 2022.
- Funds reported $120M of Nautilus Biotechnolgy stock for Q3 2022, down 23% quarter-over-quarter.
- 11 funds opened new Nautilus Biotechnolgy positions in Q3 2022 and 8 closed out, a net change of +3 holders.
- The largest Nautilus Biotechnolgy buyer in Q3 2022 was Morgan Stanley, an estimated $448K added.
- The largest Nautilus Biotechnolgy seller in Q3 2022 was RTW Investments, an estimated $1.26M sold.
Based on aggregated 13F filings for Q3 2022.